Form 4: Ocular Therapeutix Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 1,895 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 1,895 shares of common stock on February 24, 2025.
- The sale was executed at a weighted average price of $6.84 per share.
- The shares were sold to cover tax withholding obligations related to the vesting of restricted stock units on February 22, 2025.
- The sale was conducted under a pre-arranged automatic sale instruction adopted on February 21, 2024.
- Following the transaction, Nayak still beneficially owns 283,485 shares of Ocular Therapeutix common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction related to tax obligations, which is neither particularly positive nor negative.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| February 21, 2024 | Reporting person adopted a durable automatic sale instruction. |
| February 22, 2025 | Restricted stock units vested, triggering tax withholding obligations. |
| February 24, 2025 | Sanjay Nayak sold 1,895 shares of common stock. |
| February 26, 2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.